DHA and X-Linked Retinitis Pigmentosa
Retinitis Pigmentosa, X-linked Genetic Diseases
About this trial
This is an interventional prevention trial for Retinitis Pigmentosa focused on measuring retina, electroretinography, clinical trial, docosahexaenoic acid, omega-3 fatty acid, x-linked inheritance
Eligibility Criteria
Inclusion Criteria: Diagnosis of RP by a retinal specialist Clinical diagnosis consistent with X-linked inheritance Enrolling minors and young adults (early onset of X-linked disease; ages 7 to 32) Measurable cone ERG responses --patients with less than 0.64 microvolt response to 31-Hz flicker will be excluded as they are more likely to become undetectable during the study Both eyes must meet entry criteria as both will be tested (i.e., no cataracts requiring surgery or retinal detachments). Media clarity sufficient for fundus photography Able to return to study site at yearly intervals Willing to supply blood samples at 6-month intervals Judiciously take the placebo or DHA supplement for the 4-year study duration Patient/parent/guardian understands and signs consent form. Exclusion Criteria: Excessive fish consumption (e.g., cold water fish such as salmon, tuna, sardines) and/or fish oil supplementation (or other oil containing DHA) Baseline RBC-DHA levels showing evidence of supplementation (a typical level of RBC-DHA in normals is about 3.8%) Chronic metabolic disease that may interfere with fatty acid metabolism or require anti-coagulant medication No ethnic or racial groups will be excluded.
Sites / Locations
- Retina Foundation of the Southwest
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1.
2
Oral Docosahexaenoic acid, dosage based on body weight
corn/soy oil placebo; oil not containing DHA...dosage based on body weight